|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Margini C and Dufour JF: The story of HCC
in NAFLD: From epidemiology, across pathogenesis, to prevention and
treatment. Liver Int. 36:317–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang YF and Ho M: Humanization of
high-affinity antibodies targeting glypican-3 in hepatocellular
carcinoma. Sci Rep. 6:338782016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagy ZB, Wichmann B, Kalmár A, Galamb O,
Barták BK, Spisák S, Tulassay Z and Molnár B: Colorectal adenoma
and carcinoma specific miRNA profiles in biopsy and their
expression in plasma specimens. Clin Epigenetics. 9:222017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oka S, Furukawa H, Shimada K, Hashimoto A,
Komiya A, Fukui N, Tsuchiya N and Tohma S: Plasma miRNA expression
profiles in rheumatoid arthritis associated interstitial lung
disease. BMC Musculoskelet Disord. 18:212017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Zhang X, Zhang Z, Chang J, Wang Z,
Wu Z, Wang C, Sun Z, Ge X, Geng R, et al: Plasma microRNA-based
signatures to predict 3-year postoperative recurrence risk for
stage II and III gastric cancer. Int J Cancer. 141:2093–2102. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao B, Ning S, Li J, Liu H, Wei W, Wu F,
Tang Y, Feng Y, Li K and Zhang L: Integrated analysis of
differentially expressed mRNAs and miRNAs between hepatocellular
carcinoma and their matched adjacent normal liver tissues. Oncol
Rep. 34:325–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song J, Bai Z, Han W, Zhang J, Meng H, Bi
J, Ma X, Han S and Zhang Z: Identification of suitable reference
genes for qPCR analysis of serum microRNA in gastric cancer
patients. Dig Dis Sci. 57:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weber JA, Baxter DH, Zhang S, Huang DY,
Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12
body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bašová P, Pešta M, Sochor M and Stopka T:
Prediction potential of serum miR-155 and miR-24 for relapsing
early breast cancer. Int J Mol Sci. 18(pii): E21162017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qu Y, Zhang H, Sun W, Han Y, Li S, Qu Y,
Ying G and Ba Y: MicroRNA-155 promotes gastric cancer growth and
invasion by negatively regulating transforming growth factor-β
receptor 2. Cancer Sci. 109:618–628. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu F, Song D, Wu Y, Liu X, Zhu J and Tang
Y: MiR-155 inhibits proliferation and invasion by directly
targeting PDCD4 in non-small cell lung cancer. Thorac Cancer.
8:613–619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS
and Zhou T: Upregulation of microRNA-155 promotes the migration and
invasion of colorectal cancer cells through the regulation of
claudin-1 expression. Int J Mol Med. 31:1375–1380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Al-Haidari A, Algaber A, Madhi R, Syk I
and Thorlacius H: MiR-155-5p controls colon cancer cell migration
via post-transcriptional regulation of human antigen R (HuR).
Cancer Lett. 421:145–151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu X, Wen H, Jing L, Yang Y, Wang W, Liang
X, Nan K, Yao Y and Tian T: MicroRNA-155-5p promotes hepatocellular
carcinoma progression by suppressing PTEN through the PI3K/Akt
pathway. Cancer Sci. 108:620–631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Guo Y, Wu J, Chen F, Dai Z, Fan
S, Li P and Song T: Roles of microRNA-99 family in human glioma.
Onco Targets Ther. 9:3613–3619. 2016.PubMed/NCBI
|
|
22
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan B, Fu Q, Lai L, Tao X, Fei Y, Shen J,
Chen Z and Wang Q: Downregulation of microRNA 99a in oral squamous
cell carcinomas contributes to the growth and survival of oral
cancer cells. Mol Med Rep. 6:675–681. 2012.PubMed/NCBI
|
|
24
|
Yin H, Ma J, Chen L, Piao S, Zhang Y,
Zhang S, Ma H, Li Y, Qu Y, Wang X and Xu Q: MiR-99a enhances the
radiation sensitivity of non-small cell lung cancer by targeting
mTOR. Cell Physiol Biochem. 46:471–481. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Jin H, Liu H, Lv S, Wang B, Wang
R, Liu H, Ding M, Yang Y, Li L, et al: MiRNA-99a directly regulates
AGO2 through translational repression in hepatocellular carcinoma.
Oncogenesis. 3:e972014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li W, Chang J, Wang S, Liu X, Peng J,
Huang D, Sun M, Chen Z, Zhang W, Guo W and Li J: miRNA-99b-5p
suppresses liver metastasis of colorectal cancer by down-regulating
mTOR. Oncotarget. 6:24448–24462. 2015.PubMed/NCBI
|
|
27
|
He K, Tong D, Zhang S, Cai D, Wang L, Yang
Y, Gao L, Chang S, Guo B, Song T, et al: miRNA-99b-3p functions as
a potential tumor suppressor by targeting glycogen synthase
kinase-3β in oral squamous cell carcinoma Tca-8113 cells. Int J
Oncol. 47:1528–1536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y,
Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes
cell proliferation, migration and invasion by targeting PTPN9 in
breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshino H, Seki N, Itesako T, Chiyomaru T,
Nakagawa M and Enokida H: Aberrant expression of microRNAs in
bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B,
Xie Y, Ye Y and Liu J: Circulating exosomal microRNA-96 promotes
cell proliferation, migration and drug resistance by targeting
LMO7. J Cell Mol Med. 21:1228–1236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iwai N, Yasui K, Tomie A, Gen Y, Terasaki
K, Kitaichi T, Soda T, Yamada N, Dohi O, Seko Y, et al: Oncogenic
miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in
hepatocellular carcinoma. Int J Oncol. 53:237–245. 2018.PubMed/NCBI
|
|
32
|
Chen Y, Dong X, Yu D and Wang X: Serum
miR-96 is a promising biomarker for hepatocellular carcinoma in
patients with chronic hepatitis B virus infection. Int J Clin Exp
Med. 8:18462–18468. 2015.PubMed/NCBI
|
|
33
|
Leung WK, He M, Chan AW, Law PT and Wong
N: Wnt/β-catenin activates MiR-183/96/182 expression in
hepatocellular carcinoma that promotes cell invasion. Cancer Lett.
362:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
